



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number : **0 555 149 A1**

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number : **93400283.3**

(51) Int. Cl.<sup>5</sup> : **A61K 31/47**

(22) Date of filing : **04.02.93**

(30) Priority : **07.02.92 JP 56677/92**  
**20.02.92 JP 69382/92**

(43) Date of publication of application :  
**11.08.93 Bulletin 93/32**

(84) Designated Contracting States :  
**DE FR GB**

(71) Applicant : **mitsubishi gas chemical**  
**company, inc.**  
**No. 5-2, Marunouchi 2-chome**  
**Chiyoda-ku, Tokyo (JP)**

(71) Applicant : **SAGAMI CHEMICAL RESEARCH**  
**CENTER**  
**11-1, Marunouchi 1-chome Chiyoda-ku**  
**Tokyo (JP)**

(72) Inventor : **Tsuji, Tomoko**  
**6-12-2, Nookendai, Kanazawa-ku**  
**Yokohama-shi, Kanagawa 236 (JP)**  
Inventor : **Yamaguchi, Kohji**  
**1-9-1, Minamidai**  
**Sagamihara-shi, Kanagawa 228 (JP)**  
Inventor : **Kondo, Kiyosi**  
**5-16-4, Chuo-Rinkan**  
**Yamato-shi, Kanagawa 242 (JP)**  
Inventor : **Urakami, Teizi, c/o MITSUBISHI GAS**  
**CHEMICAL CO. INC**  
**2-5-2, Marunouchi**  
**Chiyoda-ku, Tokyo 100 (JP)**

(74) Representative : **Bourgognon, Jean-Marie et al**  
**Cabinet Flechner 22, Avenue de Friedland**  
**F-75008 Paris (FR)**

(54) **Nerve growth factor production accelerators and compositions for preventing or treating neuronal degeneration.**

(57) Nerve growth factor production accelerating agents containing oxazopyrroloquinolines, pyrroquinolinequinones and/or their esters as active ingredient are provided. As the oxazopyrroloquinolines and their esters exhibit such production accelerating activity, they are suitably utilized for preventing and treating functional disorders of central nervous system, particularly, Alzheimer's dementia, cerebral ischemia and spinal trauma, as well as for functional disorders of peripheral nervous system, particularly, peripheral nervous system trauma and diabetic neurosis. As the pyrroquinolinequinones and their esters exhibit strong nerve growth factor production accelerating activity, they are suitably utilized for preventing and treating functional disorders of peripheral nervous system, particularly, peripheral nervous system trauma, diabetic neurosis, etc.

EP 0 555 149 A1

This invention relates to pharmaceuticals, particularly, those for treating or preventing retrograde neural diseases, such as dementia senilis and Alzheimer's disease, and further to production accelerators for nerve growth factor (hereinafter referred to as NGF) which works for the recovery of neural function in central and peripheral nervous system diseases. Furthermore, it relates to compositions for preventing or treating neuronal degeneration.


NGF is a nutrition and growth factor necessary for the growth and maintenance of neuronal tissues, which is considered to be essential for maturation and differentiation of sensory and sympathetic nerves in the peripheral nervous system, and magnocellular cholinergic neurons in the central nervous system, as well as for life maintenance. It has, thus, been thought that the increase in the NGF level serves for the treatments of central functional disorders, such as Alzheimer's disease, vascular dementia and spinal trauma, and peripheral functional disorders, such as peripheral nervous trauma and diabetic neuronal disorders.

However, NGF is a protein with the molecular weight of 13,000 as monomer and 26,000 as dimer, so that it can not pass through the blood-brain barrier. Accordingly, it has been thought preferable that an agent accelerating the production of NGF in the living body, rather than NGF itself, is administered to promote bio-synthesis of NGF, thereby to improve disorders of the central and peripheral nervous system. Thus, investigations to seek NGF production accelerators have been attempted.

Catecholamines, such as epinephrine, norepinephrine and dopamine, have been found as agents having NGF production accelerating activity. However, because these compounds are a kind of hormones, their administration to accelerate the NGF synthesis accompanies some side effects due to quantitatively ill-balanced hormones in the living body. Therefore, satisfactory drugs have not yet been discovered from the practical point of view.

The present inventors have extensively studied on NGF production accelerating agents on account of the reasons as mentioned above, and accomplished the present invention, based upon the findings that oxazopyrroloquinolines, pyrroloquinolinequinones, and their esters exhibit the NGF production accelerating activity. Accordingly, the present invention is to provide an NGF production accelerating agent containing an oxazopyrroloquinoline or pyrroloquinolinequinone and/or their esters as active ingredient.

The term, oxazopyrroloquinolines (hereinafter referred to as OPQs), used herein means 2,8,10-tricarboxy-1H-oxazo[5,4-h]-pyrrolo[2,3-f]quinolines (OPQ) and 5-substituted compounds thereof. The OPQs and their esters are represented by the following formula:



[wherein R represents a hydrogen atom or an alkyl group having 1-4 carbon atoms, which may be substituted with a hydroxyl, carboxyl, mercapto, carbamoyl, hydroxyphenyl, guanidyl, imidazolyl, or methylmercapto group, and R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> represent a hydrogen atom or an alkyl, alkenyl or benzyl group which may be same or different.]

OPQs employed in the present invention can readily be prepared by a process wherein a pyrroloquinolinequinone compound or its salt (hereinafter referred to as PQQ, which will be explained more minutely below) is allowed to react with an  $\alpha$ -amino acid, methylamine or the like in the presence of oxygen. The reaction is usually undertaken in an aqueous medium like a microbial culture. The pH of the reaction mixture is usually in the range from 2 to 10, and the reaction temperature is practically in the range from 20 to 100°C. And the reaction time is preferably within 24 hours.

OPQs in the present invention include OPQ (R=H) obtained from a PQQ and any of glycine, threonine, tryptophan, proline, tyrosine, serine, and monomethylamine [Japanese Patent Publication (Laid-Open) No. 294281/1991]; hydroxymethyl-OPQ obtained from a PQQ and serine [Japanese Patent Publication (Laid-Open) No. 123782/1991]; 1-methylethyl-OPQ obtained from a PQQ and valine [Japanese Patent Publication


(Laid-Open) No. 170484/1991]; 1-methylpropyl-OPQ obtained from a PQQ and isoleucine [Japanese Patent Publication (Laid-Open) No. 170485/1991]; 2-methylpropyl-OPQ obtained from a PQQ and leucine [Japanese Patent Publication (Laid-Open) No. 170486/1991]; methyl-OPQ obtained from a PQQ and alanine [Japanese Patent Publication (Laid-Open) No. 188081/1991]; 2-carboxyethyl-OPQ obtained from a PQQ and glutamic acid [Japanese Patent Publication (Laid-Open) No. 190882/1991]; 2-carbamoyl-ethyl-OPQ obtained from a PQQ and glutamine [Japanese Patent Publication (Laid-Open) No. 188082/1991]; 2-methylthioethyl-OPQ obtained from a PQQ and methionine [Japanese Patent Publication (Laid-Open) No. 19088/1991]; benzyl-OPQ obtained from a PQQ and phenylalanine [Japanese Patent Publication (Laid-Open) No. 190881/1991]; 4-hydroxyphenylmethyl-OPQ obtained from a PQQ and tyrosine [Japanese Patent publication (Laid-Open) No. 9387/1992]; carboxymethyl-OPQ obtained from a PQQ and aspartic acid; carbamoylmethyl-OPQ obtained from a PQQ and asparagine; 4-imidazolylmethyl-OPQ obtained from a PQQ and histidine; 4-aminobutyl-OPQ obtained from a PQQ and lysine; 3-guanidinopropyl-OPQ obtained from a PQQ and arginine; and mercapto-methyl-OPQ obtained from a PQQ and cysteine. As shown above, R group of each OPQs basically corresponds to the R group of  $\alpha$ -amino acid [R-CH(NH<sub>2</sub>)COOH] which is used for substrate to produce one of OPQs. When the tyrosine is used as  $\alpha$ -amino acid, OPQ (R=H) is main product in the case that the pH value of the reaction mixture is low and 4-hydroxyphenylmethyl OPQ (R=CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>OH) is main product in the case that the value is high.

Salts of these OPQs include alkali metal salts, alkali earth metal salts, ammonium salts and substituted ammonium salts, which are also effective as the NGF production accelerating agents. Typical examples are the salts of sodium, potassium, magnesium, calcium, ammonium, trimethylammonium, triethylammonium, and triethanolammonium.

Esters of these OPQs include those in which R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> in the formula mentioned above represent a hydrogen atom, or an alkyl, alkenyl, or benzyl group, which may be same or different, to form mono-, di- or triesters. These OPQs esters can be prepared by a conventional process wherein an OPQs or its salt is allowed to react with an alcohol. The alkyl group may be a methyl or ethyl group, and the alkenyl group may be an allyl group.

These objective OPQs esters can also be obtained by a conventional process wherein a PQQ or its salt is allowed to react with an alcohol to give the corresponding PQQ ester, and then the ester is allowed to react with an amino acid or methylamine.

PQQs have been found as a coenzyme for methanol dehydrogenase in methanol-metabolizing bacteria. The term, PQQs, used herein means 4,5-dihydro-4,5-dioxo-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid (PQQ) and its salts. The PQQs and their esters are represented by the following formula:



[wherein in R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> represent a hydrogen or an alkyl, alkenyl, benzyl, propargyl or alkoxy-carbonylalkyl group, which may be same or different.]

PQQs and their esters actively accelerate NGF production, but they can not increase the NGF level in cerebral cortex, though they exhibit the production accelerating activity to sciatic nerve in animal experiments. Therefore, they are suitably used as preventing and therapeutic agents for degenerations of peripheral nervous system, such as peripheral nervous trauma and diabetic neurosis.

PQQs employed in this invention can be prepared by any of organic chemical syntheses [for example, that mentioned in J.A.C.S. Vol. 103, pages 5599-5600 (1981)] and fermentation methods [for example, that mentioned in Japanese Patent Publication (Laid-Open) No. 218597/1989]. PQQs referred to in this invention means PQQ and its salts, such as sodium and potassium salts of PQQ.

In the above formula for PQQ esters, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> represent a hydrogen atom, or alkyl, alkenyl, benzyl, propargyl or alkoxy-carbomethyl group, which may be same or different, to form mono-, di- or triesters. The

alkyl group may be a methyl or ethyl group, and the alkenyl group may be an allyl group.

PQQ triesters are readily synthesized by reaction of a PQQ with an alcohol [see, for example, Japanese Patent Publications (Laid-Open) Nos. 123781/1991 and 145492/1991]. PQQ monoesters or diesters can be obtained by partial hydrolysis of a PQQ triester under basic condition. PQQ diesters can also be obtained by reaction of a PQQ monoester with an alcohol under suitably selected reaction conditions of the temperature and the period of time.

OPQs and PQQs and their esters in this invention may be administered orally or non-orally. In case of oral administration, they may be administered in the form of conventional formulations such as capsules, tablets, and powders. In case of non-oral administration, the formulations may be those for injections and parenteral fluids. Sustained release formulations are also effective.

Dosage and dosing time vary depending on symptoms, ages, body weights, dosing formulations, and others, but they may be administered ordinarily in an amount of 1-500 mg a day for adults in case of oral administration, or 0.1-100 mg at once or in several times in case of non-oral administration.

In preparing formulations of the active ingredients of this invention, any additives, such as surface active agents, excipients, coloring agents, preservatives, coating auxiliaries, and the like may be suitably used. They may also be used in combination with other pharmaceuticals.

Hereinafter, examples are illustrated in order to show the NGF production accelerating activity of PQQs, OPQs and their esters, according to the present invention. These examples are, however, never construed to limit the invention.

#### Example 1

L-M cells of fibroblast cell line originated from a mouse connective tissue were suspended in a 199 culturing medium (manufactured by Flow Laboratories) containing 0.5% peptone (manufactured by Difco Laboratories), and the suspension was placed in a microplate with 96 flat bottom holes to make the cell numbers of  $2 \times 10^4$  /hole, which was then incubated in a CO<sub>2</sub> incubator (at 37°C, in an atmosphere of 5% CO<sub>2</sub> and 95% air) for 3 days. Each incubated liquid was replaced by a 199 medium containing OPQ of each given concentration and 0.5% bovine serum albumin (manufactured by Armour Pharmaceutical) or the same medium containing no OPQ, and incubated in a CO<sub>2</sub> incubator.

After 24 hour incubation, the amount of NGF contained in the supernatant fluid was estimated by enzyme immunoassay [see Korsching and Thoenen, Proc. Natl. Acad. Sci., U.S.A., 80, 3513-3516, (1983)]. The results are shown in Table 1.

Table 1

Amount of OPQ added (μg/ml)	Amount of NGF produced (pg/ml)	Relative activity (%)
0	170	100
3.1	203	119
6.3	278	164
12.5	371	218
25	367	216
50	422	248
100	288	169

#### NGF assay

A solution of anti-mouse β-NGF antibody (made by using β-NGF prepared from mouse submaxillary gland as antigen) was dispensed to each hole on a 96 hole microplate made of polystyrene (MS-3496F, manufactured by Sumitomo Bakelite Co. Ltd.) in an amount of 50 μl/hole, and stood for 4 hours at 37°C. The antibody not adsorbed to each hole of the microplate was removed, and each hole was rinsed 3 times with a cleansing liquor. A solution of standard β-NGF (manufactured by Toyobo Co., Ltd.) or a sample solution was dispensed to each hole in an amount of 40 μl/hole, and stood for 18 hours at 4°C. Then, the standard β-NGF or sample solution (incubated supernatant as mentioned above) was removed, and each hole was rinsed 3 times. A solution of

anti- $\beta$ -NGF monoclonal antibody labeled with  $\beta$ -galactosidase (manufactured by Boehringer Mannheim) (40 mU/ml, pH 7.6) was dispensed to each hole in an amount of 50  $\mu$ l/hole, and stood for 4 hours at 37°C. Then, the enzyme-labeled antibody was removed, and each hole was rinsed 3 times. A solution of 4-methylumbelliferyl- $\beta$ -galactoside (manufactured by Sigma) was dispensed to each hole in an amount of 100  $\mu$ g/hole, and allowed to react for 1.5 hours at room temperature, and then a 0.2 M glycine-sodium hydroxide buffer (pH 10.3) was dispensed to each hole in an amount of 100  $\mu$ l/hole to stop the enzyme reaction. Fluorescent intensity of 4-methylumbelliferone produced was estimated using a plate reader, and NGF amount was calculated from the standard curve. The results are shown in Table 1. NGF production accelerating activity of the tested compound was shown as a relative value (%) of the NGF amount produced by cells treated with the testing compound against the NGF amount produced by untreated cells without testing compound.

#### Example 2

Procedure of Example 1 was repeated using hydroxymethyl-OPQ, in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 2.

Table 2

Amount of hydroxymethyl-OPQ added ( $\mu$ g/ml)	Amount of NGF produced (pg/ml)	Relative activity (%)
0	384	100
0.8	525	137
1.6	554	144
3.1	565	147
6.3	582	152
12.5	593	154
25	670	174
50	708	184
100	786	205
200	982	258
400	1,453	378

#### Example 3

Procedure of Example 1 was repeated using methyl-OPQ, in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 3.

Table 3

	Amount of methyl-OPQ added ( $\mu\text{g/ml}$ )	Amount of NGF produced (pg/ml)	Relative activity (%)
5	0	384	100
	0.8	525	137
	1.6	604	157
10	3.1	599	156
	6.3	665	173
	12.5	665	173
15	25	632	165
	50	676	176
	100	681	177
20	200	873	227
	400	1,075	280

#### 25 Example 4

Procedure of Example 1 was repeated using 2-carboxyethyl-OPQ, in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 4.

Table 4

	Amount of 2-carboxyethyl-OPQ added ( $\mu\text{g/ml}$ )	Amount of NGF produced (pg/ml)	Relative activity (%)
30	0	264	100
35	1.6	330	125
	3.1	387	147
	6.3	330	125
40	12.5	349	132
	25	356	135
	50	368	139
45	100	381	144
	200	381	144
	400	454	172

50

#### Example 5

Procedure of Example 1 was repeated using benzyl-OPQ, in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 5.

55

Table 5

	Amount of benzyl-OPQ added ( $\mu\text{g/ml}$ )	Amount of NGF produced (pg/ml)	Relative activity (%)
5	0	264	100
	1.6	375	142
	3.1	368	139
10	6.3	375	142
	12.5	349	132
	25	375	142
15	50	356	135
	100	317	120
	200	298	113
20	400	271	103

## Example 6

25 Procedure of Example 1 was repeated using 1-methylpropyl -OPQ, in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 6.

Table 6

	Amount of 1-methylpropyl-OPQ added ( $\mu\text{g/ml}$ )	Amount of NGF produced (pg/ml)	Relative activity (%)
30	0	264	100
	1.6	442	167
35	3.1	446	177
	6.3	430	163
	12.5	418	158
40	25	484	183
	50	430	163
	100	381	144
45	200	337	128
	400	245	93

## 50 Example 7

Procedure of Example 1 was repeated using 2-methylpropyl -OPQ, in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 7.

55

Table 7

	Amount of 2-methylpropyl-OPQ added ( $\mu\text{g/ml}$ )	Amount of NGF produced (pg/ml)	Relative activity (%)
5	0	264	100
	1.6	460	174
	3.1	400	152
10	6.3	460	174
	12.5	424	161
	25	436	165
15	50	478	181
	100	418	158
	200	393	149
20	400	324	123

## Example 8

25 Procedure of Example 1 was repeated using 2-methylthioethyl -OPQ, in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 8.

Table 8

	Amount of 2-methylthioethyl-OPQ added ( $\mu\text{g/ml}$ )	Amount of NGF produced (pg/ml)	Relative activity (%)
30	0	264	100
	1.6	490	186
35	3.1	442	167
	6.3	484	183
	12.5	430	163
40	25	466	177
	50	480	186
	100	424	161
45	200	356	135
	400	349	132

## Example 9

50 Procedure of Example 1 was repeated using 2-carbamoylethyl -OPQ, in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 9.

55

Table 9

	Amount of 2-carbamoylethyl-OPQ added ( $\mu\text{g/ml}$ )	Amount of NGF produced (pg/ml)	Relative activity (%)
5	0	382	100
	0.8	443	116
	1.6	512	134
10	3.1	505	132
	6.3	546	143
	12.5	632	165
15	25	639	167
	50	652	171
	100	566	148
20	200	512	134
	400	408	107

#### 25 Example 10

Procedure of Example 1 was repeated using 1-methylethyl -OPQ, in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 10.

Table 10

	Amount of 1-methylethyl-OPQ added ( $\mu\text{g/ml}$ )	Amount of NGF produced (pg/ml)	Relative activity (%)
30	0	382	100
35	0.8	386	101
	1.6	478	125
	3.1	492	129
40	6.3	526	138
	12.5	546	143
	25	553	145
45	50	606	159
	100	573	150
	200	539	141
50	400	485	127

#### Example 11

55 Procedure of Example 1 was repeated using 4-hydroxyphenylmethyl -OPQ, in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 11.

Table 11

	Amount of 4-hydroxyphenylmethyl- OPQ added ( $\mu\text{g/ml}$ )	Amount of NGF produced (pg/ml)	Relative activity (%)
5	0	382	100
	0.8	560	147
	1.6	580	152
10	3.1	553	145
	6.3	632	165
	12.5	613	160
15	25	613	160
	50	652	171
	100	429	112
20	200	335	88

## Example 12

25 Procedure of Example 1 was repeated using OPQ methyl ester at 2-position (OPQ-2-ME), in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 12.

Table 12

	Amount of OPQ-2-ME added ( $\mu\text{g/ml}$ )	Amount of NGF produced (pg/ml)	Relative activity (%)
30	0	259	100
	0.8	290	112
35	1.6	299	115
	3.1	299	115
	6.3	344	133
40	12.5	308	119
	25	234	90

## Example 13

45 Procedure of Example 1 was repeated using OPQ methyl ester at 7-position (OPQ-7-ME), in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 13.

50

55

Table 13

Amount of OPQ-7-ME added ( $\mu\text{g/ml}$ )	Amount of NGF produced (pg/ml)	Relative activity (%)
0	219	100
0.8	217	99
1.6	265	121
3.1	242	111
6.3	234	107
12.5	235	107
25	266	121

## Example 14

Procedure of Example 1 was repeated using OPQ dimethyl ester at 2- and 7-positions (OPQ-2,7-DME), in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 14.

Table 14

Amount of OPQ-2,7-DME added ( $\mu\text{g/ml}$ )	Amount of NGF produced (pg/ml)	Relative activity (%)
0	259	100
0.8	299	115
1.6	345	133
3.1	336	130
6.3	317	122
12.5	326	126
25	274	106

## Example 15

Procedure of Example 1 was repeated using OPQ dimethyl ester at 2- and 9-positions (OPQ-2,9-DME), in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 15.

Table 15

Amount of OPQ-2,9-DME added (µg/ml)	Amount of NGF produced (pg/ml)	Relative activity (%)
0	259	100
0.8	249	96
1.6	290	112
3.1	342	132
6.3	373	144
12.5	435	168
25	393	152
50	258	100

## Example 16

Procedure of Example 1 was repeated using OPQ trimethyl ester (OPQ-TME), in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 16.

Table 16

Amount of OPQ-TME added (µg/ml)	Amount of NGF produced (pg/ml)	Relative activity (%)
0	336	100
0.8	508	151
1.6	677	201
3.1	636	189
6.3	628	187
12.5	653	194
25	563	168
50	524	156
100	516	154
200	587	175
400	508	151

## Example 17

Procedure of Example 1 was repeated using OPQ 2-methyl-7,9-diethyl ester (OPQ-2-ME-7,9-DEE), in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 17.

Table 17

Amount of OPQ-ME-7,9-DEE added (µg/ml)	Amount of NGF produced (pg/ml)	Relative activity (%)
0	381	100
0.8	476	125
1.6	558	146
3.1	542	142
6.3	576	151
12.5	716	188
25	625	164
50	608	160
100	421	110

## Example 18

Procedure of Example 1 was repeated using PQQ- $\text{Na}_2$ , in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 18.

Table 18

Amount of PQQ- $\text{Na}_2$ added (µg/ml)	Amount of NGF produced (pg/ml)	Relative activity (%)
0	204	100
0.8	319	156
1.6	302	148
3.1	398	195
6.3	677	332
12.5	1,076	527
25	2,515	1,233
50	5,915	2,900
100	8,034	3,938
200	5,428	2,661
400	2,487	1,219

## Example 19

Procedure of Example 1 was repeated using PQQ dipotassium salt (PQQ- $\text{K}_2$ ), in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 19.

Table 19

Amount of PQQ-K <sub>2</sub> added (µg/ml)	Amount of NGF produced (pg/ml)	Relative activity (%)
0	384	100
0.8	560	146
1.6	554	144
3.1	729	190
6.3	812	211
12.5	1,453	378
25	3,288	856
50	7,047	1,835
100	7,281	1,896
200	4,425	1,152
400	1,237	322

## Example 20

Procedure of Example 1 was repeated using PQQ methyl ester at 2-position (PQQ-2-ME), in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 20.

Table 20

Amount of PQQ-2-ME added (µg/ml)	Amount of NGF produced (pg/ml)	Relative activity (%)
0	727	100
0.8	1,434	197
1.6	1,663	229
3.1	2,501	344
6.3	3,126	430
12.5	4,510	620
25	5,611	772
50	5,188	714
100	2,397	330

## Example 21

Procedure of Example 1 was repeated using PQQ methyl ester at 7-position (PQQ-7-ME), in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 21.

Table 21

Amount of PQQ-7-ME added ( $\mu\text{g/ml}$ )	Amount of NGF produced (pg/ml)	Relative activity (%)
0	219	100
1.6	258	118
3.1	282	129
6.3	493	225
12.5	1,238	565
25	1,448	661
50	928	424
100	335	153
200	266	121

## Example 22

Procedure of Example 1 was repeated using PQQ dimethyl ester at 2- and 9-positions (PQQ-2,9-DME), in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 22.

Table 22

Amount of PQQ-2,9-DME added ( $\mu\text{g/ml}$ )	Amount of NGF produced (pg/ml)	Relative activity (%)
0	727	100
0.8	1,165	160
1.6	1,777	244
3.1	3,126	430
6.3	3,790	521
12.5	4,790	659
25	6,829	939
50	5,499	756
100	4,584	631
200	1,852	255

## Example 23

Procedure of Example 1 was repeated using PQQ trimethyl ester (PQQ-TME), in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 23.

Table 23

Amount of PQQ-TME added ( $\mu\text{g/ml}$ )	Amount of NGF produced (pg/ml)	Relative activity (%)
0	341	100
0.8	429	126
1.6	464	136
3.1	600	176
6.3	954	280
12.5	1,448	425
25	2,852	836
50	3,015	884
100	1,678	492

## Example 24

Procedure of Example 1 was repeated using PQQ triethyl ester (PQQ-TEE), in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 24.

Table 24

Amount of PQQ-TEE added ( $\mu\text{g/ml}$ )	Amount of NGF produced (pg/ml)	Relative activity (%)
0	381	100
0.8	2,190	575
1.6	2,160	567
3.1	1,889	496
6.3	1,882	494
12.5	1,249	328
25	550	144

## Example 25

Procedure of Example 1 was repeated using PQQ triallyl ester (PQQ-TAE), in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 25.

Table 25

Amount of PQQ-TAE added (µg/ml)	Amount of NGF produced (pg/ml)	Relative activity (%)
0	204	100
0.8	403	198
1.6	414	203
3.1	611	300
6.3	776	380
12.5	1,063	521
25	707	347

Example 26

Procedure of Example 1 was repeated using PQQ triethoxycarbonylmethyl ester (PQQ-TECE), in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 26.

Table 26

Amount of PQQ-TECE added (µg/ml)	Amount of NGF produced (pg/ml)	Relative activity (%)
0	381	100
3.1	428	112
6.3	455	119
12.5	558	146
25	669	176
50	1,908	508
100	3,092	812
200	304	80

Example 27

Procedure of Example 1 was repeated using PQQ tripropargyl ester (PQQ-TPGE), in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 27.

Table 27

Amount of PQQ-TPGE added ( $\mu\text{g/ml}$ )	Amount of NGF produced ( $\text{pg/ml}$ )	Relative activity (%)
0	381	100
1.6	389	102
3.1	599	157
6.3	764	201
12.5	2,453	644
25	6,022	1,581
50	3,926	1,030
100	505	133

## Example 28

L-M cells were incubated in similar way as in Example 1 using epinephrine which has been known as an NGF production accelerator, in place of OPQ, to estimate its NGF production accelerating activity. The results are shown in Table 28.

Table 28

Amount of epinephrine added ( $\mu\text{g/ml}$ )	Amount of NGF produced ( $\text{pg/ml}$ )	Relative activity (%)
0	179	100
0.8	180	101
1.6	168	94
3.1	180	101
6.3	187	104
12.5	224	125
25	319	178
50	431	241
100	872	487
200	259	144

Epinephrine showed NGF product ion accelerating activity at an amount of not less than 12.5  $\mu\text{g/ml}$ , and exhibited the maximum value (about 500%) at an amount of 100  $\mu\text{g/ml}$ . On the other hand, OPQs and OPQ esters showed almost the same degree of NGF production accelerating activity as shown in Examples 1-17. Also, PQQs and PQQ esters gave high activity values even at a lower concentration, having markedly higher NGF production accelerating activity, when compared with epinephrine.

## Example 29

L-M cells were incubated in similar way as in Example 1.

In three groups (A, B and C) of L-M cell incubation system, Group A contained no tested compound, Group B contained 100  $\mu\text{g/ml}$  of PQQ- $\text{Na}_2$ , and Group C contained 275  $\mu\text{g/ml}$  of epinephrine. Amounts of NGF produced during the course of times (3, 6, 9, 12, 24, 30, 36 and 48 hours from the beginning of incubation) were estimated. The results are shown in Table 29.

As obvious from the table, addition of PQQ-  $\text{Na}_2$  definitely increases NGF production, as compared with

the cases of no addition and adding epinephrine.

Table 29

Incubating period of time (hr)	Amount of NGF produced (pg/ml)		
	(A) No addition	(B) PQQ-Na <sub>2</sub> 100 µg/ml added	(C) Epinephrine 275 µg/ml added
0	63	81	66
3	124	180	92
6	219	667	202
9	254	2,657	288
12	271	4,947	347
24	378	9,924	556
30	420	8,635	689
36	458	8,334	873
48	465	7,769	1,960

### Example 30

SD female rats ( 7 weeks age, 160-190 g) were put under anesthesia by intramuscularly administering 25 mg of ketamine hydrochloride and 0.25 mg of doloperidol. Left femor sciatic nerve was exposed and cut off, and the cut ends were connected with a gap of about 2 mm using a silicone tube (1 mm inner diameter, 6 mm length). The gap between the cut ends was filled with an isotonic sodium chloride solution. After reduction of the operational cut, each 0.5 ml of an aqueous 2% gum arabic solution containing a given concentration of OPQ was administered intraperitoneally. As control, 0.5 ml of an aqueous 2% gum arabic solution containing no OPQ was administered intraperitoneally. As for positive control, the gap of the cut ends of sciatic nerve was filled with an isotonic sodium chloride solution containing 1 mg/ml of NGF, and 0.5 ml of an aqueous 2% gum arabic solution containing no OPQ was administered intraperitoneally. After 4 weeks from the operation, animals were sacrificed by cervical bertebral luxation, and the reproduced sciatic nerves were collected. Cross sectional slices of the reproduced sciatic nerves were prepared and dyed with hemathoxyl in-eosine, and number of the reproduced nerve fibers was counted.

The results are shown in Table 30. As obvious from the table, number of the reproduced sciatic nerves was much increased by administering OPQ, which was comparable to direct inject ion of NGF.

Table 30

Amount of OPQ administered (µg/kg rat)	Number of reproduced sciatic nerves	Relative activity (%)
0	12,590	100
5	12,600	100
10	12,848	102
50	13,912	111
100	19,839	158
500	17,870	142
Positive control (NGF gap injection)	20,932	166

## Example 31

Procedure of Example 30 was repeated using OPQ trimethyl ester (OPQ-TME), in place of OPQ, to estimate the reproduction accelerating activity of OPQ-TME for sciatic nerve. The results are shown in Table 31.

As obvious from the table, number of the reproduced sciatic nerves was much increased by administering OPQ-TME, which was comparable to NGF.

Table 31

Amount of OPQ-TME administered ( $\mu\text{g/kg}$ rat)	Number of reproduced sciatic nerves	Relative activity (%)
0	12,590	100
5	11,860	94
10	11,193	89
50	12,780	102
100	22,966	182
500	26,313	209
Positive control (NGF gap injection)	20,932	166

## Example 32

Procedure of Example 30 was repeated using PQQ- $\text{Na}_2$ , in place of OPQ, to estimate the reproduction accelerating activity for sciatic nerve. The results are shown in Table 32.

As obvious from the table, number of the reproduced sciatic nerves was much increased by administering OPQ- $\text{Na}_2$ , which was comparable to NGF.

Table 32

Amount of PQQ- $\text{Na}_2$ administered ( $\mu\text{g/kg}$ rat)	Number of reproduced sciatic nerves	Relative activity (%)
0	12,590	100
5	16,984	135
10	21,822	173
50	26,142	208
100	18,247	145
500	14,031	111
Positive control (NGF gap injection)	20,932	166

## Example 33

Procedure of Example 30 was repeated using PQQ trimethyl ester (PQQ-TME), in place of OPQ, to estimate its reproduction accelerating activity for sciatic nerve. The results are shown in Table 33.

As obvious from the table, number of the reproduced sciatic nerves was much increased by administering PQQ-TME, which was comparable to NGF.

Table 33

Amount of PQQ-TME administered ( $\mu\text{g/kg}$ rat)	Number of reproduced sciatic nerves	Relative activity (%)
0	12,590	100
5	19,047	151
10	21,054	167
50	24,940	198
100	17,882	142
500	17,902	142
Positive control (NGF gap injection)	20,932	166

## Example 34

OPQ trimethyl ester (OPQ-TME) was suspended in 0.5 ml of an aqueous 2% gum arabica in a given concentration, and the suspension was administered to Wistar male rats (8-10 weeks age, 200-250 g) intraperitoneally. Administrations were conducted every other days once a day, 4 times in total. After 2 days from the last administration, rats were dissected under anesthesia, and the neocortex, submaxillary gland and hippocampus were collected. The following procedures were conducted under ice-cooling. Each of these tissues was weighed, and mixed with a 20 time-volume of a phosphate buffer (8 g/l of NaCl, 0.2 g/l of KCl, 1.15 g/l of  $\text{Na}_2\text{HPO}_4$  and 0.2 g/l of  $\text{KH}_2\text{PO}_4$ ), and the mixture was homogenized by an ultrasonic crusher, followed by centrifugation at  $10,000 \times G$  for 30 minutes to separate the supernatant. Amount of NGF contained in the supernatant was estimated by enzyme immunoassay. The results are shown in Table 34. NGF amount (ng) per 1 mg (wet weight) of neocortex, submaxillary gland or hippocampus was set forth as the average value  $\pm$  standard error from 3 heads tested simultaneously. As for former two tissues, relative activities were also shown against the case of no OPQ-TME administration.

As obvious from the table, NGF contents in neocortex and submaxillary gland were increased by administering OPT-TME. Particularly, the degree of increase was high in neocortex.

Table 34

Amount of OPQ-TME administered ( $\mu\text{g/kg}$ rat)	Neocortex		Submaxillary gland		Hippocampus
	NGF (ng/mg tissue wet weight)	Relative activity (%)	NGF (ng/mg tissue wet weight)	Relative activity (%)	NGF (ng/mg tissue wet weight)
0	$1.83 \pm 0.05$	100	$0.63 \pm 0.04$	100	$2.44 \pm 0.23$
0.1	$2.64 \pm 0.17$	144	$0.70 \pm 0.05$	111	$2.31 \pm 0.20$
0.5	$2.60 \pm 0.40$	142	$0.85 \pm 0.06$	135	$2.20 \pm 0.46$
1.0	$3.17 \pm 0.44$	173	$0.67 \pm 0.09$	106	-

## Example 35

Procedure of Example 34 was repeated using PQQ trimethyl ester (PQQ-TME), in place of OPQ-TME, to estimate the accelerating activities of PQQ-TME for NGF contents of neocortex, submaxillary gland and hippocampus. The results are shown in Table 35.

Administration of PQQ-TME did not increase the NGF contents in neocortex, submaxillary gland and hippocampus. Supposedly, PQQ-TME have no NGF production accelerating activity to central nervous system.

Table 35


Amount of PQQ-TME administered (mg/kg rat)	NGF production amount (ng/mg tissue wet weight)		
	Neocortex	Submaxillary gland	Hippocampus
0	2.51±0.23	1.42±0.07	2.53±0.23
0.1	2.25±0.10	1.67±0.15	2.44±0.04
0.5	2.19±0.33	1.58±0.07	2.10±0.15
1.0	2.71±0.30	1.30±0.08	-

Thus, as OPQs and their esters exhibit NGF production accelerating activity, and, in animal experiments, they increase the NGF content in neocortex, and accelerate reproduction of sciatic nerve, the nerve growth factor production accelerators of the present invention are suitably utilized as preventive and therapeutic agents for functional disorders of central nervous system, particularly, Alzheimer's dementia, cerebral ischemia and spinal trauma, as well as for functional disorders of peripheral nervous system, particularly, peripheral nervous system trauma and diabetic neurosis.

Further, as PQQs and their esters exhibit strong NGF production accelerating activity, and, in animal experiments, they accelerate the reproduction of sciatic nerve, the present accelerators are suitably utilized as preventing and treating agents for functional disorders of peripheral nervous system, particularly, peripheral nervous system trauma, diabetic neurosis, etc.


### Claims

1. A nerve growth factor production accelerating composition which comprises an oxazopyrroloquinoline or its ester represented by the following formula as active ingredient:




[wherein R represents a hydrogen atom or an alkyl group having 1-4 carbon atoms, which may be substituted with a hydroxyl, carboxyl, mercapto, carbamoyl, hydroxyphenyl, guanidyl, imidazolyl or methylmercapto group, and R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> represent a hydrogen atom or an alkyl, arkenyl or benzyl group, which may be same or different.]

2. The use for preventing or treating degeneration of central or peripheral nervous system of an oxazopyrroloquinoline or its ester represented by the following formula:




[wherein R represents a hydrogen atom or an alkyl group having 1-4 carbon atoms, which may be substituted with a hydroxyl, carboxyl, metcapto, carbamoyl, hydroxyphenyl, guanidyl, imidazolyl or methylmercapto group, and R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> represent a hydrogen atom or an alkyl, arkenyl or benzyl group, which may be same or different.]

3. A nerve growth factor production accelerating composition which comprises a pyrroloquinol inequinone or its ester represented by the following formula as active ingredient:



[wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> represent a hydrogen atom or an alkyl, alkenyl, benzyl, propargyl or alkoxycarbonylalkyl group, which may be same or different.]

4. The use for preventing or treating degeneration of peripheral nervous system of a pyrroloquinol inequinone and/or its ester represented by the following formula:



[wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> represent a hydrogen atom or an alkyl, alkenyl, benzyl, propargyl or alkoxycarbonylalkyl group, which may be same or different.]



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number

EP 93 40 0283

Page 1

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
D,X	EP-A-0 429 333 (MISUBISHI GAS CHEMICAL COMPANY, INC.) * page 3, line 1 - page 5, line 2 *	1-4	A61K31/47
P,X	US-A-5 091 391 (ELIAS AIZENMAN ET AL.) 25 February 1992 * column 2, line 55 - column 4, line 4 *	3,4	
X	DATABASE WPIL Week 9049, Derwent Publications Ltd., London, GB; AN 90-364855 & JP-A-226 581 (FUJI CHEMICAL IND KK) * abstract *	3,4	
Y	---	2	
X	DATABASE WPIL Week 9037, Derwent Publications Ltd., London, GB; AN 90-279255 & JP-A-2 196 720 (FUJI CHEMICAL IND KK) * abstract *	3,4	
Y	---	2	TECHNICAL FIELDS SEARCHED (Int. Cl.5)
P,X	THE JOURNAL OF NEUROSCIENCE vol. 12, no. 6, June 1992, pages 2362 - 2369 ELIAS EIZENMAN ET AL. 'Interaction of the putative essential nutrient pyrroloquinoline quinone with the N-methyl-D-aspartate receptor redox modulatory site' * abstract *	3,4	A61K
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 28 APRIL 1993	Examiner TZSCHOPPE D. A.
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

EPO FORM 1501 (01/91) (P0001)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number

EP 93 40 0283  
Page 2

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
D,X	DATABASE WPIL Week 9207, Derwent Publications Ltd., London, GB; AN 92-052015 & JP-A-3 294 281 (MISUBISHI GAS CHEMICAL COMPANY, INC.) * abstract *	1	
Y	---	2	
P,X	EP-A-0 505 226 (MISUBISHI GAS CHEMICAL COMPANY, INC.) * claim 3 *	1,3	
			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 28 APRIL 1993	Examiner TZSCHOPPE D. A.
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : technological background O : non-written disclosure P : intermediate document & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

EPO FORM 1503 (12/92) (P0001)